NetFlow: A tool for isolating carbon flows in genome-scale metabolic networks.

Genome-scale stoichiometric models (GSMs) have been widely utilized to predict and understand cellular metabolism. GSMs and the flux predictions resulting from them have proven indispensable to fields ranging from metabolic engineering to human disease. Nonetheless, it is challenging to parse these flux predictions due to the inherent size and complexity of the GSMs.

NetRed, an algorithm to reduce genome-scale metabolic networks and facilitate the analysis of flux predictions.

Flux balance analysis (FBA) of large, genome-scale stoichiometric models (GSMs) is a powerful and popular method to predict cell-wide metabolic activity. FBA typically generates a flux vector containing O(1,000) fluxes. The interpretation of such a flux vector is difficult, even for expert users, because of the large size and complex topology of the underlying metabolic network.

Achieving a Predictive Understanding of Antimicrobial Stress Physiology through Systems Biology.

The dramatic spread and diversity of antibiotic-resistant pathogens has significantly reduced the efficacy of essentially all antibiotic classes, bringing us ever closer to a postantibiotic era. Exacerbating this issue, our understanding of the multiscale physiological impact of antimicrobial challenge on bacterial pathogens remains incomplete. Concerns over resistance and the need for new antibiotics have motivated the collection of omics measurements to provide systems-level insights into antimicrobial stress responses for nearly 20 years.

Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophy.

Spinal muscular atrophy (SMA), a leading genetic cause of infant death worldwide, is an autosomal recessive disorder caused by the loss of SMN1 (survival motor neuron 1), which encodes the protein SMN. The loss of SMN1 causes a deficiency in SMN protein levels leading to motor neuron cell death in the anterior horn of the spinal cord. SMN2, however, can also produce some functional SMN to partially compensate for loss of SMN1 in SMA suggesting increasing transcription of SMN2 as a potential therapy to treat patients with SMA.